DIA Annual Canadian Meeting 2016

Short Courses: October 17 | Meeting: October 18-19 | Ottawa Marriott Hotel | Ottawa, Ontario, Canada

PROGRAM CO-CHAIRS

Marilena Bassi, MA
Acting Director, BPSIP
Health Canada

Deirdre Cozier
Senior Manager, Regulatory Affairs (Canada) Pendopharm, Division of Pharmascience

PROGRAM COMMITTEE

Loretta Del Bosco
Director, Regulatory Affairs and Quality Assurance Operations
AbbVie Corporation, Canada

Laura Durno, MSc
Acting Chief, Viral Vaccines Division, Biologics and Genetic Therapies Directorate
Health Canada

Karen Feltmate
President
Redstone Health Group, Inc., Canada

Maggie Graham
Senior Policy Advisor, Natural and Non-Prescription Health Products Directorate
Health Canada

Vratislav Hadrava, MD, PhD
Vice President and Medical Director, Global Innovative Products
Pfizer Canada, Inc., Canada

Keith McIntosh
Executive Director, Scientific and Regulatory Affairs
Innovative Medicines Canada

Marc F. Poitras, PhD, MBA
Scientific Manager, Marketed Pharmaceuticals and Medical Devices Bureau
Health Canada

Matthew Ryan
Senior Policy Analyst; Policy, Planning and International Affairs Directorate
Health Canada

Overview

Innovation to support collaboration, engagement, and openness across the Canadian health care landscape.

What does innovation mean to you? Join key thought leaders, industry experts, academics, medical professionals, and Health Canada representatives, and explore how innovation can drive and support new initiatives, regulatory processes, research, transparency, engagement, personalized medicine, use of real-world data, and much more!

Who Should Attend

Professionals involved in:

- Regulatory Affairs
- Policy
- Pharmacoeconomics
- Clinical Development
- Medical Affairs
- Drug Safety/ Pharmacovigilance
- Patient Safety
- Medical Communications
- Quality Operations

Highlights

Keynote Speaker Joelle Pineau, PhD
The AI Revolution: New Perspectives on Health Care in the Information Age

- Short Course: *Plain Language Labeling: Implementing Health Canada's Guidance for Industry*
  October 17 | 8:30AM-12:00PM
- Short Course: *Innovation in Rx-to-OTC Switch*
  October 17 | 1:30-5:00PM
- Community Outreach Activity with the Children's Hospital of Eastern Ontario (CHEO)
  October 17 | 5:00-6:00PM
- Tabletop exhibitors

Schedule At-A-Glance

SHORT COURSES | MONDAY, OCTOBER 17

7:30AM-5:00PM	Short Course Registration	Cartier Foyer, Lower Level
8:30AM-12:00PM	**Short Course 1:** Plain Language Labeling: Implementing Health Canada's Guidance for Industry	Cartier III, Lower Level
1:30-5:00PM	**Short Course 2:** Innovation in Rx-to-OTC Switch	Cartier III, Lower Level
5:00-6:00PM	Community Outreach Activity with the Children's Hospital of Eastern Ontario (CHEO)	Victoria Ballroom B, Ballroom Level

DAY ONE | TUESDAY, OCTOBER 18

8:00AM-5:00PM	Registration	Victoria Ballroom Foyer, Ballroom Level
8:00-9:00AM	Continental Breakfast, Exhibits, and Networking	Victoria Ballroom Foyer, Ballroom Level
9:00-9:15AM	Welcome and Opening Remarks	Victoria Ballroom, Ballroom Level
9:15-10:00AM	**Session 1: Keynote Address** The AI Revolution: New Perspectives on Health Care in the Information Age	Victoria Ballroom, Ballroom Level
10:00-10:30AM	Refreshments, Exhibits, and Networking Break	Victoria Ballroom Foyer, Ballroom Level
10:30AM-12:00PM	**Session 2: Plenary Session** Setting Strategic Direction - A View from the Regulators and Industry	Victoria Ballroom, Ballroom Level
12:00-1:30PM	Luncheon and Networking	Cartier I - III, Lower Level
1:30-3:00PM	**Session 3: Track A:** Regulatory Processes – Innovations **Track B:** Regulatory Operations **Track C:** Science and Product Development	Victoria Ballroom A, Ballroom Level Victoria Ballroom B, Ballroom Level Laurier Salon, Lower Level
3:00-3:30PM	Refreshments, Exhibits, and Networking	Victoria Ballroom Foyer, Ballroom Level
3:30-5:00PM	**Session 4: Track A:** Enhancing Innovation **Track B:** New Digital Solutions for Canadian Product Monograph **Track C:** Personalized Medicine	Victoria Ballroom A, Ballroom Level Victoria Ballroom B, Ballroom Level Laurier Salon, Lower Level
5:00-6:00PM	Exhibits and Networking Reception	Victoria Ballroom Foyer, Ballroom Level

DAY TWO | WEDNESDAY, OCTOBER 19

7:30AM-3:00PM	Registration	Victoria Ballroom Foyer, Ballroom Level
7:30-8:30AM	Continental Breakfast, Exhibits, and Networking Break	Victoria Ballroom Foyer, Ballroom Level
8:30-10:00AM	**Session 5: Track A:** Transparency and Openness **Track B:** Data/Analytics **Track C:** Generics and Biosimilars	Victoria Ballroom A, Ballroom Level Victoria Ballroom B, Ballroom Level Laurier Salon, Lower Level
10:00-10:30AM	Refreshments, Exhibits, and Networking Break	Victoria Ballroom Foyer, Ballroom Level
10:30AM-12:00PM	**Session 6: Track A:** Policy Development and Direction **Track B:** Patient Care/Patient Voice/Engagement – Role of Patient Associations **Track C:** Risk Assessment and Risk Management	Victoria Ballroom A, Ballroom Level Victoria Ballroom B, Ballroom Level Laurier Salon, Lower Level
12:00-1:30PM	Luncheon and Networking	Cartier I-III, Lower Level
1:30-3:00PM	**Session 7: Plenary Session** Health Canada's International Regulatory Forum Speakers: International Perspectives	Victoria Ballroom, Ballroom Level

Learning objectives

At the conclusion of this meeting, participants should be able to:

- Describe the current and evolving regulatory environment in Canada
- Analyze the current innovations in Canada's health care and medical product development landscapes
  - Summarize methods and approaches to instill innovation in various aspects of clinical trials, patient engagement, supply chain, and manufacturing
- Discuss the compliance, medical, legal, and regulatory considerations for social media use in the medical product development process
- Review and examine the various levels of transparency that have been introduced into Canada's health care landscape

Continuing Education Credit

DIA has been accredited as an Authorized Provider by the International Association for Continuing Education and Training (IACET).

As an IACET Authorized Provider, DIA offers CEUs for its programs that qualify under the ANSI/IACET Standard. DIA is authorized by IACET to offer 1.0 CEUs for this program. Participants must attend the entire program in order to be able to receive an IACET statement of credit. No partial credit will be awarded. Participants will be able to download a statement of credit upon successful submission of the credit request. My Transcript will be available for credit requests on **Wednesday, November 2, 2016.**

If you would like to receive a statement of credit, you must attend the conference or short course, sign in at the DIA registration desk each day, and complete the online credit request process through My Transcript. Participants will be able to download a statement of credit upon successful submission of the credit request. My Transcript will be available for credit requests beginning **Wednesday, November 2, 2016.**

Access My Transcript

- Visit DIAglobal.org, select "Sign in" and you will be prompted for your user ID and password
- Choose MENU, found in the upper left corner
- Under CONFERENCES select "Continuing Education"
- Select the blue "My Transcript" button followed by "Credit Request" to process your credit request for the course

View DIA's Grievance Policy at DIAglobal.org/Grievance

Access Presentations

- Visit DIAglobal.org
- Select 'Sign in' at the top right
- Enter your User ID and Password
- Go to 'My Account'
- View 'My Presentations'

DIA User ID and Password are needed to access presentations. If you have forgotten your DIA User ID and Password, or this is your first time logging into the DIA website, please use our Login Reminder.

MONDAY, OCTOBER 17

7:30AM-5:00PM — **Registration**

8:30AM-12:00PM

Short Course 1: Plain Language Labeling: Implementing Health Canada's Guidance for Industry

Instructors

Rebecca Bose
Policy Analyst
Health Canada

Sonya DaCosta, RN
Regulatory Affairs Labeling Manager
Apotex Inc., Canada

Christine Leroux
Senior Regulatory Project Manager
Health Canada

Veronica Yip
Acting Manager, Labeling Division
Health Canada

Rocelyn DelCarmen
Director, Regulatory Affairs and Quality Assurance
AstraZeneca, Inc., Canada

Building upon the content presented during the 2015 Plain Language Labeling Short Course, this course will review Health Canada's requirements for Plain Language Labeling, discuss operational changes that have been implemented over the past year, and offer an opportunity to discuss concrete examples. Tips and strategies to facilitate the implementation of Health Canada's Guidance for Industry will also be discussed.

Learning Objectives

At the conclusion of this short course, participants should be able to:

- Explain the principles and concepts of Plain Language Labeling
- Describe Health Canada's requirements for Plain Language Labeling and understand the operational changes that have been implemented
- Prepare drug label and packaging documents according to Health Canada's Guidance for Industry

1:30-5:00PM

Short Course 2: Innovation in Rx-to-OTC Switch

Instructors

Angelina Habimana, MSc
Regulatory Lead, GEM, CHC and Operations
Sanofi Canada

John Wong, MPharm
Executive Director, Regulatory Drug Advertising and Promotion
Therapeutic Products Inc., Canada

Kristin Willemsen, MS
Director of Scientific and Regulatory Affairs
Consumer Health Products Canada

Ratna Bose, PMP
Health Canada

Michelle O'Connor Coughlan
AmerisourceBergen, Director, Strategic Consulting
Innomar Strategies, Canada

With the ability to do direct-to-consumer advertising and limited price controls, the regulatory professional is often solicited to evaluate the potential applicability of the switch process to many drug candidates. As the switch process is one that involves regulators at both the federal and provincial level, a detailed understanding of the process is crucial. When asked to evaluate potential switch candidates, regulatory professionals need to be able to answer some of the following questions:

- How long will the switch take and what will it cost?
- Will competitors be able to use the switch to their advantage?
- Will the labeling be similar? Are there any specific packaging requirements? (such as tamper/child-resistant)? Can we add promotional claims to the packaging?
- What data is needed to support the switch?

Learning Objectives

At the conclusion of this short course, participants should be able to:

- Review the process to switch a RX product to OTC status
- Discuss the challenges and benefits in Rx-to-OTC switch for key stakeholders

5:00-6:00PM Join us in giving back to the community!

This year, we are partnering with the Children's Hospital of Eastern Ontario (CHEO) to kick off the *DIA Annual Canadian Meeting 2016* with a community outreach activity!

Help us say 'thank you' by supporting the leaders of tomorrow at CHEO, whose focus is on creating cures and implementing the newest technologies and advancements in medicine to ensure children can thrive in their community.

TUESDAY, OCTOBER 18

8:00AM-5:00PM — **Registration**

8:00-9:00AM — **Continental Breakfast, Exhibits, and Networking**

9:00-9:15AM — **Welcome and Opening Remarks**

Sudip Parikh, PhD
Senior Vice President and Managing Director,
DIA Americas
DIA

9:15-10:00AM — **Session 1: Keynote Address**
The AI Revolution: New Perspectives on Health Care in the Information Age

Session Co-Chairs
Marilena Bassi, MA
Acting Director, BPSIP
Health Canada

Deirdre Cozier
Senior Manager, Regulatory Affairs (Canada)
Pendopharm, Division of Pharmascience, Canada

Keynote Speaker
Joelle Pineau, PhD
Associate Professor, School of Computer Science
Director Cognitive Science Program
McGill University, Canada

Explore new methods for automatically discovering and optimizing sequential treatments for chronic and life-threatening diseases using recent methods from Artificial Intelligence and Machine Learning. In particular, we will focus on how you can use data collected in multi-stage sequential trials to automatically generate treatment strategies that are tailored to patient characteristics and time-dependent outcomes. We will also examine promising methods to improve the efficiency of clinical trials through adaptation. Examples will be drawn from several ongoing research projects on developing new treatment strategies for epilepsy, mental illness, diabetes, and cancer.

Q&A

10:00-10:30AM — **Refreshments, Exhibits, and Networking Break**

10:30AM-12:00PM — **Session 2: Plenary Session**
Setting Strategic Direction - A View from the Regulators and Industry

Session Co-Chairs
Marilena Bassi, MA
Acting Director, BPSIP
Health Canada

Deirdre Cozier
Senior Manager, Regulatory Affairs (Canada)
Pendopharm, Division of Pharmascience,
Canada

Speakers
Brian O'Rourke
President and Chief Executive Officer
Canadian Agency for Drugs and
Technologies in Health, Canada

Pierre Sabourin
Assistant Deputy Minister, Health
Products and Food Branch
Health Canada

Senior leaders from both government and industry will discuss renewal and strategic priority setting within their respective organizations. You will have the opportunity to learn about the future directions of these key organizations, their priorities for the coming years, and how each is evolving and changing to be better positioned to meet emerging trends and issues. There will be an opportunity to ask questions and explore the concepts in more detail.

TUESDAY, OCTOBER 18

12:15-1:30PM — **Luncheon and Networking**

1:30-3:00PM — **Session 3**

Track A
Regulatory Processes – Innovations

Session Chair
Maggie Graham
Senior Policy Advisor, Natural and Non-Prescription Health Products Directorate
Health Canada

Canadian consumers have access to more health information than ever before and are making more decisions about how to improve and maintain their health with the use of products that they can choose and use on their own. Health Canada is modernizing the way these consumer health products are regulated. Understanding the consumer experience with self-care products is key to developing an effective regulatory framework and ensuring Canadian consumers have the information and tools that support informed decision-making. This session will provide an overview of the ways Health Canada is engaging with consumers and stakeholders beyond the use of traditional consultation methods.

Amanda Moir
Senior Policy Advisor, Consumer Health Products Modernization
Health Canada

Kristin Willemsen, MS
Director of Scientific and Regulatory Affairs
Consumer Health Products Canada, Canada

Maggie Graham
Senior Policy Advisor, Natural and Non-Prescription Health Products Directorate
Health Canada

Track B
Regulatory Operations

Session Chair
Matthew Ryan
Senior Policy Analyst; Policy, Planning and International Affairs Directorate
Health Canada

The regulatory operations field is one that has always quickly evolved to leverage opportunities to improve processes through technological innovations in the areas of document and information management. These health authority initiatives also come with challenges and increasing complexities. In order to fully leverage these innovative technologies, process adaptation will be required. This session will provide you with an overview of innovative technologies and processes available or under development by Health Canada to improve operational effectiveness. Presenters will discuss the tools (REP, eCTD v4.0, SPL, ESG) and the strategies to fully leverage these innovations and highlight potential issues and challenges to overcome.

eCTD v4.0: The Path to Implementation

Jared Lantzy, PMP
Manager, Global Regulatory Agencies and Processes
LORENZ Life Sciences Group

Innovation Through Regulatory Operational Processes: Impact on Compliance, Efficiency, and Competitiveness

Khaled Yahiaoui, MSc, RAC
Manager, Regulatory Operations
Pharmascience Inc., Canada

Vianney Caron
Manager Electronic Regulatory Activities
Health Canada

Track C
Science and Product Development

Session Chair
Laura Durno, MSc
Acting Chief, Viral Vaccines Division
Biologics and Genetic Therapies Directorate
Health Canada

Developing and implementing new technologies, manufacturing processes, and clinical trials in the biotechnology industry requires an understanding and cooperation between the innovator and the regulator. The session will discuss the challenges and conversations that need to happen between both parties in regards to innovative approaches in order to advance a product through clinical development and, ultimately, to market.

Interacting with Regulators to Facilitate New Technologies in the Biotechnology Industry

Anthony R. Mire-Sluis, PhD
Head of Global Quality
Astrazeneca

Product, Process Understanding, and Statistical Process Control: PV Life Cycle Approach

Marzena Ingram
Manager, Process Validation, GSO-Technical Operations Validation
Apotex Inc. - Signet, Canada

Daniel L. Keene, MD, MA, FRCPC
Senior Medical Officer, CERB
Health Canada (BGTD)

Catherine Njue, PhD
Bisostatistics Advisor - Clinical Trials, CERB
Health Canada (BGTD)

TUESDAY, OCTOBER 18

3:00-3:30PM — **Refreshments, Exhibits, and Networking**

3:30-5:00PM — **Session 4**

Track A
Enhancing Innovation

Session Co-Chairs

Rocelyn DelCarmen
Director, Regulatory Affairs and Quality Assurance
AstraZeneca, Inc., Canada

Keith McIntosh
Executive Director, Scientific and Regulatory Affairs
Innovative Medicines Canada

Encouraging an environment in which innovation thrives is a priority for the government and for industry alike. The regulatory processes that govern the conduct of business within the pharmaceutical sector must be aligned to achieve this goal as well as being competitive with other similar jurisdictions to attract, retain, and deliver innovative health care solutions to the Canadian population. In this session, Health Canada and industry speakers will discuss options to close the gaps in the current regulatory framework and processes surrounding new product submissions to enable faster access to new therapies.

Progress on Implementation of Vanessa's Law to Date and Future Amendments

Kristen Beausoleil
Senior Policy Advisor, Office of Legislative and Regulatory Modernization
Health Canada

Supporting Innovation in the Regulatory Landscape – Thoughts from Innovative Medicine Canada

Loretta Del Bosco
Director, Regulatory Affairs Quality Assurance Operations
AbbVie Corporation, Canada

Track B
New Digital Solutions for Canadian Product Monograph

Session Chair

Vratislav Hadrava, MD, PhD
Vice President and Medical Director, Global Innovative Products
Pfizer Canada, Inc., Canada

This session will describe the challenges and solutions that are being explored by pharmaceutical manufacturers with the Canadian Pharmacists Association to ensure that Health Canada approved, Patient Medication Information is made easily available to pharmacists across Canada.

Justin Scanlon
Vice President, Digital and Print Offerings
Canadian Pharmacists Association, Canada

Arshia Ghani
Associate Director, Regulatory Affairs
Pfizer Canada Inc., Canada

The 2016 Canadian Product Monograph Guidance

Michelle Remillard
Manager, Health Products and Food Branch
Health Canada

Track C
Personalized Medicine

Session Co-Chairs

Karen Feltmate
President
Redstone Health Group, Inc., Canada

Laura Durno, MSc
Acting Chief, Viral Vaccines Division
Biologics and Genetic Therapies Directorate
Health Canada

This session will provide a scientific overview and definition of personalized medicine. Presentations will include advances in the field and challenges faced with respect to intellectual property rights, regulatory approval, reimbursement policies, and patient confidentiality.

The Keys to a Successful Personalized Medicine Strategy

Stephen Amato, PhD, MBA, RAC
Head of Graduate Faculty, Regulatory Affairs; Associate Teaching Professor
Northeastern University – College of Professional Studies

George Wyatt
Managing Director
Wyatt Health Management, Canada

Katherine M. Soltys, MD
Manager, Health Products and Food Branch
Health Canada

5:00-6:00PM — **Exhibits and Networking Reception**

WEDNESDAY, OCTOBER 19

7:30AM-3:30PM	**Registration**
7:30-8:30AM	**Continental Breakfast, Exhibits, and Networking**
8:30-10:00AM	**Session 5**

Track A
Transparency and Openness

Session Chair
Vratislav Hadrava, MD, PhD
Vice President and Medical Director,
Global Innovative Products
Pfizer Canada, Inc., Canada

The session will review the pre-market transparency initiatives underway within the Health Products and Food Branch, provide updates and next steps, the evolution of the post-market clinical data transparency within industry, the different models of data sharing initiatives, and industry endorsement of data sharing principles.

Jessica S. Scott, DrMed, JD, MD
Director, North America Medical
Advocacy and Policy
GlaxoSmithKline

Update on Premarket Transparency in the Health Products and Food Branch, Health Canada

Laura Johnson
Project Manager
Health Canada

Rebecca Bose
Policy Analyst
Health Canada

Clinical Trial Data Transparency: A Brief History and Current Directions

Sandra Morris, PhD, PMP
Vice President, Strategic Realization
Johnson & Johnson

Marla Jo Brickman, PhD
Senior Director/Team Leader,
Clinical Trial Disclosure Group
Pfizer Inc.

Track B
Data/Analytics

Session Chair
Karen Feltmate
President
Redstone Health Group, Inc., Canada

Mobile Health (mHealth) and patient access to their own health records offer two of the strongest opportunities to deliver best value for money by significantly reducing inappropriate admissions and readmissions by extending care into our communities and to the care-giver/patient. This session will present as a panel discussion, assessing the challenges and opportunities for adoption of mHealth solutions and patient access/input to their own health records, as well as the regulatory and policy options to eliminate barriers to adoption of mobile and digital health solutions.

Mobile Health Lead Canadian Advanced Technology Alliance

David Farnes, MA
Mobile Health Lead
Canadian Advanced Technology
Alliance, Canada

Shurjeel Choudhri, DrMed, FRCP
Senior Vice President and Head,
Medical and Scientific Affairs
Bayer Inc., Canada

Suzanne Rochford, MSc
Director, User Centered Design,
Documentation and Training
TELUS Health, Canada

Tyson Roffey
Head of Canadian Healthcare Solutions
and Social Innovation
Hitachi, Canada

Track C
Generics and Biosimilars

Session Chair
Loretta Del Bosco
Director, Regulatory Affairs Quality
Assurance Operations
AbbVie Corporation, Canada

This session will provide an overview of generics and biosimilars from a regulator, industry, and industry consultant perspective. The field of generics continues to evolve and Canada is entering into the new era of biosimilars. What are the challenges? What are the opportunities? How are generics and biosimilars different? Hear from Subject Matter Experts on this exciting and sometimes controversial topic.

Donald Elrick, PhD
Director, Regulatory Affairs, Immunology
Janssen Inc., Canada

Policy in the Development of Generics and Biosimilars in Canada

Anne Tomalin, RAC
President
Therapeutic Products Inc., Canada

Dawn Culp
Vice President, Global Regulatory
Affairs Policy
Mylan Inc.

Agnes Klein, DrPH, MD
Director, Evaluation of
Radiopharmaceuticals and
Biotherapeutic Products
Health Canada

WEDNESDAY, OCTOBER 19

10:00-10:30AM — **Refreshments, Exhibits, and Networking**

10:30AM-12:00PM — **Session 6**

Track A
Policy Development and Direction

Session Chair
Deirdre Cozier
Senior Manager, Regulatory Affairs (Canada)
Pendopharm, Division of Pharmascience, Canada

This session will overview the process of policy development at Health Canada, from conception to finalization. It will include presentations from industry on the engagement of stakeholders and thought leaders, such as patient groups and industry associations, and the different models used to interact with these groups. Additionally, we will discuss how individual companies (from small and medium sized firms to the large multinational enterprises) can contribute to policy development at the local and international level by implementing innovative regulatory intelligence processes and tools.

Health Policy Initiatives: Ideas Becoming Official Policy and Beyond

Jane Mitchell, PhD, RAC
Associate Director, Regulatory Affairs
Mapi Life Sciences Canada Inc., Canada

Stakeholder Involvement in Guidance Development

Keith McIntosh
Executive Director, Scientific and Regulatory Affairs
Innovative Medicines Canada

Linda F. Bowen, MSc, RAC
Head, US Regulatory Science and Policy
Sanofi

Track B
Patient Care/Patient Voice/ Engagement – Role of Patient Associations

Session Chair
Loretta Del Bosco
Director, Regulatory Affairs Quality Assurance Operations
AbbVie Corporation, Canada

This session will provide an overview of how Patient Associations participate and are being engaged by various stakeholders from the pharmaceutical industry to the regulator and payer to ensure that the patient voice makes a difference in patient care.

Julie Bouchard
Clinical Coordinator
CACTUS Montreal, Canada

Janet Yale
President, Chief Executive Officer, Chair of the Arthritis Alliance of Canada
Arthritis Society of Canada

Agnes Klein, DrPH, MD
Director, Evaluation of Radiopharmaceuticals and Biotherapeutic Products
Health Canada

Track C
Risk Assessment and Risk Management

Session Chair
Marc F. Poitras, PhD, MBA
Scientific Manager, Marketed Pharmaceuticals and Medical Devices Bureau
Health Canada

This session will discuss processes related to annual summary reports (PSUR/PBRER), Issue Related Summary Reports, and Risk Communications, summarizing Health Canada expectations and addressing questions/concerns. Industry/Health Canada perspectives on the implementation of related guidelines will also be presented.

Melissa Hunt, MSc
Scientific Manager
Health Canada

Patricia Carruthers-Czyzewski, MSc, RPh
Manager, Risk Communication Section
Health Canada

Agnes Jankowicz, MSc
Executive Director, PV
Certus PV Services Inc., Canada

WEDNESDAY, OCTOBER 19

12:00-1:30PM	**Luncheon and Networking**
1:30-3:00PM	**Session 7: Plenary Session** **Health Canada's International Regulatory Forum Speakers: International Perspectives** This year Health Canada is collaborating with DIA to host the *Health Canada International Regulators Forum* (IRF) immediately following the *DIA Annual Canadian Meeting*. The IRF is an annual forum hosted by Health Canada, which brings together regulators from around the globe to focus on information sharing, regulatory best practices, and capacity building. In this Closing Plenary you will hear from speakers from various regulatory agencies. This an opportunity to learn more about experiences and updates from other regulatory agencies around innovation, capacity building, challenges, and opportunities. There will be an opportunity to ask questions and explore the concepts in more detail. **Speakers Invited**
3:00PM	**Meeting Adjourns**

Exhibiting Companies

- CAPRA
- Certus PV Services Inc.
- Clinical Trials Ontario
- LORENZ Life Science
- Mapi
- Proficio Scientific Affairs
- Schlafender Hase Inc.
- Therapeutic Products Inc.

We Hope to See You Next Year!

DIA Annual Canadian Meeting 2017

Short Courses: October 16
Meeting: October 17-18

Ottawa Marriott Hotel
Ottawa, Ontario, Canada

**Picture provided by Ottawa Tourism*